Investing.com - Verona Pharma (NASDAQ:VRNA) ADR reported on Thursday second quarter earnings that beat analysts' forecasts and revenue that was inline with expectations.
Verona Pharma ADR announced earnings per share of $-0.05 on revenue of $0.00. Analysts polled by Investing.com anticipated EPS of $-0.316 on revenue of $0.00.
Verona Pharma ADR shares are down 14.71% from the beginning of the year, still down 38.59% from its 52 week high of $9.72 set on February 25. They are under-performing the Nasdaq which is up 14.68% from the start of the year.
Verona Pharma ADR follows other major Healthcare sector earnings this month
Verona Pharma ADR's report follows an earnings beat by J&J on July 21, who reported EPS of $2.48 on revenue of $23.31B, compared to forecasts EPS of $2.29 on revenue of $22.49B.
UnitedHealth had beat expectations on July 15 with second quarter EPS of $4.7 on revenue of $71.32B, compared to forecast for EPS of $4.43 on revenue of $69.51B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar